Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-11-18

Clinical Trial Update: A Study of IBI302 in Patients With nAMD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IBI302 for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBI302

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED